Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression

Molecular Oncology

Volumn 10, Issue 1, 2016, Pages 157-165

  Chang, Gregory A ^a,b   Tadepalli, Jyothirmayee S ^a,b   Shao, Yongzhao ^a,b   Zhang, Yilong ^a,b   Weiss, Sarah ^a,b   Robinson, Eric ^a,b   Spittle, Cindy ^c   Furtado, Manohar ^d   Shelton, Dawne N ^d   Karlin Neumann, George ^d   Pavlick, Anna ^a,b   Osman, Iman ^a,b   Polsky, David ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MolecularMD   (United States)

^d BIO RAD LABORATORIES   (United States)

Author keywords

Biomarker; BRAF; Circulating tumor DNA (ctDNA); Lactate dehydrogenase (LDH); Melanoma; NRAS

Indexed keywords

B RAF KINASE; CIRCULATING TUMOR DNA; DNA; LACTATE DEHYDROGENASE; RAS PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; CANCER DIAGNOSIS; CELL FREE SYSTEM; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DNA DETERMINATION; DNA EXTRACTION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTATIC MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY ANALYSIS; TUMOR VOLUME; BLOOD; GENETICS; MELANOMA; METASTASIS; MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMARKERS, TUMOR; CELL-FREE SYSTEM; DISEASE PROGRESSION; DNA, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; L-LACTATE DEHYDROGENASE; MELANOMA; MEMBRANE PROTEINS; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84953329508     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.09.005     Document Type: Article

References (26)

1. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. Dec 20 2009, 27(36):6199-6206.
2. Benesova L., Belsanova B., Suchanek S., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal. Biochem. Feb 15 2013, 433(2):227-234.
3. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. Feb 19 2014, 6(224). 224ra224.
4. Chang-Hao Tsao S., Weiss J., Hudson C., et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific Rep. 2015, 5:11198.
5. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. Jun 30 2011, 364(26):2507-2516.
6. Das Thakur M., Salangsang F., Landman A.S., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature Feb 14 2013, 494(7436):251-255.
7. Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. Mar 28 2013, 368(13):1199-1209.
8. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA Nov 8 2005, 102(45):16368-16373.
9. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. Sep 2008, 14(9):985-990.
10. Egberts F., Hitschler W.N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. Feb 2009, 19(1):31-35.
11. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. Nov 2012, 367(18):1694-1703.
12. Forbes S.A., Beare D., Gunasekaran P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. Jan 28 2015, 43(Database issue):D805-D811.
13. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. Aug 19 2010, 363(8):711-723.
14. Hodis E., Watson I.R., Kryukov G.V., et al. A landscape of driver mutations in melanoma. Cell Jul 20 2012, 150(2):251-263.
15. Hwu W., Balch C.M., Houghton A. Diagnosis of stage IV disease. Cutaneous Melanoma 2003, 523-546. Quality Medical, St. Louis. fourth ed. C.M.H.A. Balch, A. Sober, S. Soong (Eds.).
16. Lipson E.J., Velculescu V.E., Pritchard T.S., et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer 2014, 2(1):42.
17. Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. Jan 1999, 64(1):218-224.
18. Long G.V., Stroyakovskiy D., Gogas H., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. Nov 13 2014, 371(20):1877-1888.
19. (NCCN) NCCN. NCCN Clinical Practice Guidelines in Oncology. (accessed 28.01.15). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
20. Oxnard G.R., Paweletz C.P., Kuang Y., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. Mar 15 2014, 20(6):1698-1705.
21. Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. Jan 22 2015, 372(4):320-330.
22. Sanmamed M.F., Fernandez-Landazuri S., Rodriguez C., et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of Droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. Jan 2015, 61(1):297-304.
23. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. Feb 23 2012, 366(8):707-714.
24. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. Jun 28 2012, 366(26):2443-2454.
25. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. Dec 1 2009, 15(23):7412-7420.
26. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. Jul 11 2013, 369(2):122-133.